ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy

This study compares two different dyes — indocyanine green (ICG) and blue patent dye — used during surgery to identify and remove targeted lymph nodes (called targeted axillary dissection, or TAD) in breast cancer patients whose underarm lymph nodes were initially cancerous but who have received pre-surgery chemotherapy to shrink the cancer. **You may be eligible if...** - You have breast cancer that originally spread to underarm lymph nodes (cN+) - You have completed or are undergoing pre-surgery (neoadjuvant) chemotherapy **You may NOT be eligible if...** - You have a medical contraindication to using indocyanine green (ICG) dye - Your cancer has shown signs of progressing (growing) during chemotherapy Talk to your doctor to see if this trial is right for you.